Serious bradycardia and Remdesivir for COVID-19: a new safety concern
2 Mar, 2021 | 02:06h | UTC
Commentary on Twitter
⛔A new safety concern⛔
New 🔥 post-marketing study @CMIJournal suggests that the use of remdesivir is significantly associated with an increased risk of reporting serious bradycardia compared with HCQ,LPV/RTV, tocilizumab or glucocorticoids #IDTwitter https://t.co/npLMchifEM— Antibiotic Steward Bassam Ghanem 🅱️C🆔🅿️🌟 (@ABsteward) February 27, 2021